Examples of FDA approved mAbs that can mediate ADCC include trastuzumab (HER2+ breast cancer) [7], rituximab (multiple lymphomas) [8], cetuximab (advanced and metastatic colorectal cancer and head and neck cancer) [9], and avelumab (metastatic Merkel cell carcinoma in adults and pediatric patients aged ≥ 12 years and as maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma) [10, 11]. Here, ERBB2 is linked to breast carcinoma.